Mv

@olof_stranding Has the confidence in the prognosis of 50msek ebitda 2025 weakened?

Today Acuvi published the first quarter of the year. We reach 51 MSEK in sales (45) which is the best start to a year. EBITDA of 20% is good but will be better. During our first quarter, we had costs of around 2 MSEK to centralize our sales and wind down our Swiss operations. These costs have now been taken. Looking forward to the rest of the year. I will talk to Kalqyl tomorrow as usual. Feel free to ask me questions about the report directly here at X. placera.se/pressmeddeland…